Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EPS (Basic) (2023 - 2026)

Compass Therapeutics' EPS (Basic) history spans 4 years, with the latest figure at -$0.1 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 16.67% to -$0.1 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.4, a 2.44% increase, with the full-year FY2025 number at -$0.42, down 16.67% from a year prior.
  • EPS (Basic) hit -$0.1 in Q1 2026 for Compass Therapeutics, down from -$0.08 in the prior quarter.
  • Over the last five years, EPS (Basic) for CMPX hit a ceiling of -$0.06 in Q1 2023 and a floor of -$0.14 in Q2 2025.
  • Historically, EPS (Basic) has averaged -$0.09 across 4 years, with a median of -$0.09 in 2023.
  • The widest YoY moves for EPS (Basic): up 27.27% in 2025, down 50.0% in 2025.
  • Tracing CMPX's EPS (Basic) over 4 years: stood at -$0.1 in 2023, then dropped by 10.0% to -$0.11 in 2024, then increased by 27.27% to -$0.08 in 2025, then dropped by 25.0% to -$0.1 in 2026.
  • Business Quant data shows EPS (Basic) for CMPX at -$0.1 in Q1 2026, -$0.08 in Q4 2025, and -$0.08 in Q3 2025.